Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors

摘要: Background Pancreatic ductal adenocarcinoma is a particularly challenging malignancy characterized by poor responsiveness to conventional chemotherapy. Although this tumor frequently overexpresses or possesses constitutively activated variants of IGF-IR and EGFR/Her-2, clinical trials using inhibitors these receptors have failed. ErbB been proposed as one mechanism involved in the resistance inhibitors. Therefore, combined treatment with both would appear be good strategy for overcoming emergence resistance.